文献速递肝病

八周来迪派韦/索磷布韦方案对特定基因1型丙型肝炎病毒感染患者有效

Eight weeks of ledipasvir/sofosbuvir is effective for selected patients with genotype 1 hepatitis C virus infection.
PubMed 文献 · Hepatology · 2017-02-25

该研究利用真实世界队列数据评估8周来迪派韦/索磷布韦(LDV/SOF)治疗基因1型丙型肝炎病毒感染的疗效,并系统综述与Meta分析比较8周与12周方案。汇总634例8周治疗者按方案持续病毒学应答率98.1%(622/634),治疗合格者97.9%(571/583);Meta分析6个真实世界队列共5637例,8周与12周复发风险相似(相对风险=0.99,95%CI 0.98-1.00)。

要点

  • 8周LDV/SOF可用于初治、无肝硬化且治疗前病毒载量<6,000,000 IU/mL的基因1型丙型肝炎病毒感染者。
  • 汇总634例8周治疗者按方案持续病毒学应答率98.1%(622/634),治疗合格者97.9%(571/583)。
  • Meta分析显示8周与12周LDV/SOF复发风险相似(相对风险=0.99,95%CI 0.98-1.00)。

核心结论

  • 对经过适当选择的患者,8周LDV/SOF治疗高度有效;推荐更广泛地使用该方案。

研究设计与样本

  • 利用IFI、Burman's Pharmacy和Kaiser Permanente Southern California的真实世界队列个体患者数据评估8周疗效及复发相关特征,所有患者均通过活检、瞬时弹性成像或血清生物标志物评估纤维化分期。
  • 系统综述与Meta分析纳入另外6个真实世界队列,比较8周与12周LDV/SOF的疗效。

主要发现

  • 汇总数据分析中,634例患者接受8周LDV/SOF治疗,全部有治愈或复发结局且无失访。
  • 按方案12周持续病毒学应答率在全队列为98.1%(622/634),在治疗合格患者中为97.9%(571/583)。
  • 精确逻辑回归显示无特定患者特征与复发相关。
  • 对另外6个真实世界队列共5637例的Meta分析显示,8周与12周LDV/SOF的复发风险相似(相对风险=0.99,95%CI 0.98-1.00)。

关键数值与推荐

  • 8周LDV/SOF可考虑用于初治、无肝硬化且治疗前病毒载量<6,000,000 IU/mL的基因1型丙型肝炎病毒感染者。
  • 汇总634例8周治疗者按方案持续病毒学应答率为98.1%(622/634),治疗合格者(583例)为97.9%(571/583)。
  • Meta分析6个真实世界队列共5637例,8周与12周LDV/SOF复发风险相对风险=0.99(95%CI 0.98-1.00)。

临床怎么用

  • 原文推荐更广泛地使用8周LDV/SOF方案治疗经过适当选择的基因1型丙型肝炎病毒感染者。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Eight weeks duration of ledipasvir/sofosbuvir (LDV/SOF) can be considered in genotype 1 hepatitis C virus-infected patients who are treatment-naive, do not have cirrhosis, and have a pretreatment viral load <6,000,000 IU/mL. The effectiveness of this regimen, however, has not been fully confirmed by real-world experience. Using data from real-world cohorts, we aimed to determine the effectiveness of 8 weeks of LDV/SOF treatment, examine variables associated with relapse after treatment with this regimen, and compare the effectiveness of 8 weeks and 12 weeks of LDV/SOF treatment. To evaluate the effectiveness of 8 weeks of therapy and characteristics associated with relapse, we used individual patient data from the IFI (Institut für Interdisziplinäre Medizin), Burman's Pharmacy, and Kaiser Permanente Southern California. All patients had fibrosis staging assessed with biopsy, transient elastography, or serum biomarkers. We also performed a systematic review and meta-analysis of six additional real-world cohorts, to compare effectiveness of 8 weeks to 12 weeks duration. In our pooled data analysis, 634 patients were treated for 8 weeks with LDV/SOF, of whom all had outcomes of cure or relapse without loss to follow-up. Per protocol rates of sustained virologic response at 12 weeks were 98.1% (622/634) in the full cohort and 97.9% (571/583) among treatment-eligible patients. Exact logistic regression revealed no specific patient characteristics associated with relapse. Our meta-analysis of six additional real-world cohorts, comprised of 5,637 patients, demonstrated similar risk for relapse between 8 weeks and 12 weeks of LDV/SOF (relative risk = 0.99, 95% confidence interval 0.98-1.00). CONCLUSION: An 8-week duration of treatment with LDV/SOF is highly effective in properly selected patients; greater use of this regimen is recommended. (Hepatology 2017;65:1094-1103).

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Kowdley KV, Sundaram V, Jeon CY, et al. Eight weeks of ledipasvir/sofosbuvir is effective for selected patients with genotype 1 hepatitis C virus infection. Hepatology. 2017. PMID: 28027579. doi:10.1002/hep.29005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。